Compare Abeona Therapeutics Inc (ABEO) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs CDW Corp. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while CDW Corp. trades at $137.17 (market cap $17.79B). The key difference: CDW Corp. is far larger — about 47.7× Abeona Therapeutics Inc's market cap, and CDW Corp. pays a 1.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CDW | |
|---|---|---|
Market Cap | $373.32M | $17.79B |
Sector | Health | Technology |
52-Week High | $7.23 | $182.18 |
52-Week Low | $4.17 | $99.30 |
Enterprise Value | $228.22M | $23.00B |
Dividend Yield | — | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CDW trades at $139.23, up 4.39% today, near its consensus price target of $142.17. The stock shows a bullish technical trend with strong moving averages, while fundamentals reflect steady revenue of $22.42B in 2025 and robust profitability with a 44.16% ROE. Recent news highlights AI infrastructure demand fueling growth, and the company increased its share repurchase program by $1 billion in May 2026.
Outlook is positive with analyst consensus strongly bullish (70.59% buy ratings), though risks include margin pressure and competitive threats. The stock offers value with a P/E of 16.34 and growth potential from AI adoption, but investors should monitor execution on earnings targets and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
